76000 FLUOROSCOPE EXAMINATION 31654 BRONCH EBUS IVNTJ PERPH LES
76001 FLUOROSCOPE EXAM EXTENSIVE 31654 BRONCH EBUS IVNTJ PERPH LES
Radiation oncology consists of two primary treatment modalities: External Beam Radiation Therapy (EBRT) and brachytherapy. Brachytherapy is a type of radiation therapy that utilizes natural or manufactured radioactive isotopes or radionuclides that are temporarily or permanently implanted to treat malignancies or certain benign conditions and derives a physical advantage based upon the inverse square law of physics. Brachytherapy is accomplished by placing small encapsulated radioactive elements (aka, “seeds” or “sources”) directly in or near the tumor or treatment site. There are currently three basic clinical brachytherapy formats: interstitial applications, intracavitary applications (also called “intraluminal”) and surface applications (placed directly on the skin or other external target surface). Brachytherapy may use a solid radioactive source such as a seed or liquid colloid isotopes and may be either temporary or permanent. Further, brachytherapy may be high- or low-dose rate.
Brachytherapy may be used independently as the sole treatment or as an adjunctive treatment in combination with external beam therapy and/or other modalities such as surgery or chemotherapy.
Brachytherapy may be performed concomitantly with surgical resection or in conjunction with procedures such as endoscopy or angioplasty, which are required to achieve access to the site of the disease. There are two distinct phases required to complete the process known as brachytherapy: the insertion of non-radioactive applicators or conduits that receive or transmit the radioactive material into the body and the loading of the radioactive material (the active or therapeutic agent) into the conduits or directly into tissue.
The typical requirements of brachytherapy may involve:
- Treatment planning (CPT code 77263)
Brachytherapy (other than coronary, which is discussed in another policy) is routinely designated complex (77263) because it requires complex treatment volume design, dose levels near normal tissue tolerance, analysis or special tests, complex fractionation, or delivery concurrent with other therapeutic modalities or treatment of previously irradiated tissues. If brachytherapy is used as an adjunct to external beam therapy, a single complex treatment planning code is used to encompass both modalities, unless provided by a different provider in a different place of service.
- Dosimetry (CPT code 77300)
Brachytherapy requires certain calculations be made throughout the course of treatment. Each necessary basic dosimetry calculation may be submitted when performed for brachytherapy treatment.
- Special treatment procedure (CPT code 77470)
The delivery of brachytherapy often requires special arrangements with the operating room and radiation safe ward, coordination of the applicator insertion process with other specialists, preparation and provision of the applicators and related equipment, scheduling and integration of required physics support, and acquisition and preparation of the radiation sources.
Brachytherapy is often delivered in conjunction with external radiation, chemotherapy or surgery. Complex integration of these processes with brachytherapy may make a special treatment procedure code appropriate.
- Simulation (CPT codes 77280–77295)
For brachytherapy, simulation may require the use of imaging examinations of the implanted sources or applicator(s) containing dummy (i.e., non-radioactive) sources. These films of the implanted sources are used to develop isodose curves and other dosimetry and may be billed separately, when appropriate. CPT code 77295 may be billed as part of the brachytherapy process when the needed parameters are included (i.e., three-dimensional (3D) volume reconstruction with dose volume histogram for target and normal tissues, etc.). Code 77295 precludes the use of codes 77326–77328 for the same treatment volume.
Brachytherapy requires an isodose plan. The plan determines the dose at each implanted source and throughout the treatment volume and doses to surrounding normal tissue.
- Handling and loading of Radioelement (CPT code 77790)
- Source Application/Placement (CPT codes 77750, 77761–77763, 77776–77778, 77785, 77786, 77787 and 77789)
- The choice of applicators and the actual placement of the afterloading device may be performed by the radiation oncologist alone or in collaboration with another physician (e.g., gynecologist, urologist, pulmonologist).
- Treatment devices (CPT codes 77332–77334)
- Medical Physics Services (CPT codes 77331, 77336 and 77370)
- CPT code 77331 is special dosimetry (e.g., Thermoluminescent Dosimetry [TLD], microdosimetry) when prescribed by the treating physician.
- CPT code 77336 is referred to as a “weekly code” (from the common five-dose fractions per week). However, for radiation therapy treatment that may not be administered in five weekly fractions (such as brachytherapy), code 77336 may be reported once for each completed five fractions and for a completed final group of three, four or five fractions. For a course of radiation therapy consisting of only one or two fractions, code 77336 may be reported once.
- CPT code 77370 may be justified for the complex interrelationships of electron and photon ports and complex dosimetric consideration in brachytherapy, including high-dose rate remote after-loader applications, intravascular brachytherapy treatments and the interstitial radioactive seed implantation.
- LDR is usually delivered over several days in a hospital setting; however, LDR may consist of permanently implanted sources and be performed as either an ambulatory or inpatient procedure that delivers radiation as the isotope decays.
- HDR is performed by using a remote afterloading device to deliver the radioactive source(s). HDR allows the dose to be delivered customarily in minutes and usually on an outpatient basis and is often given in a series of multiple fractions.
- Pulsed-Dose Rate (PDR) Brachytherapy uses sources of intermediate strength and delivers a series of doses on a one- to two-hour schedule over a one- to two-day treatment period. It is also a form of remote after-loading.
Limitations:
- Although radiographs may be used in brachytherapy simulation, these images are not to be reported as port films.
- Follow-up visits for 90 days after treatment are not separately payable. (This does not apply to a patient visit for complaints unrelated to the current treatment.)
- Products used for the patient’s comfort may not be charged as treatment devices (e.g., pillows, pad or cushions).
- Only a physician authorized as a user by the Nuclear Regulatory Commission or an Agreement State for brachytherapy should work with radioactive materials.
The physician’s professional component for the brachytherapy procedure includes any necessary hospital admission and hospital care during the time the patient is undergoing the brachytherapy procedure. Admission, subsequent hospital care and discharge day summary are included in the global fee for brachytherapy procedures.
Breast Brachytherapy by Balloon Catheter(s)
All three requirements must be met:
- The tumor being treated is less than 3 cm or 2 cm if it is in stage T1.
- There is no cancer at the surgical margins.
- There are three or fewer lymph nodes containing cancer.
- The prior site of the tumor is a fluid-filled seroma (cavity).
- The seroma is not located directly under the skin.
- The seroma is not large or irregular in shape.
CPT code 19298 is used for placement of multiple tube or button-type catheters, whether done at the same session or subsequently, and these same above criteria must be met and documented in the record.
Compliance with the provisions in this policy is subject to monitoring by postpayment data analysis and subsequent medical review.
Contractors shall consider a service to be reasonable and necessary if the contractor determines that the service is:
- Safe and effective.
- Not experimental or investigational (exception: routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000, which meet the requirements of the clinical trials NCD are considered reasonable and necessary).
- Appropriate, including the duration and frequency that is considered appropriate for the service, in terms of whether it is:
- Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient’s condition or to improve the function of a malformed body member.
- Furnished in a setting appropriate to the patient’s medical needs and condition.
- Ordered and furnished by qualified personnel.
- One that meets, but does not exceed, the patient’s medical need.
- At least as beneficial as an existing and available medically appropriate alternative.
Bill Type Codes
Revenue Codes
Note:
|
Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book. The American Medical Association (AMA) and the Centers for Medicare & Medicaid Services (CMS) require the use of short CPT descriptors in policies published on the Web.
|
17999©
|
Skin tissue procedure
|
19296©
|
Place po breast cath for rad
|
19297©
|
Place breast cath for rad
|
19298©
|
Place breast rad tube/caths
|
31643©
|
Diag bronchoscope/catheter
|
43241©
|
Upper gi endoscopy with tube
|
55860©
|
Surgical exposure prostate
|
57155©
|
Insert uteri tandems/ovoids
|
57156©
|
Ins vag brachytx device
|
58346©
|
Insert heyman uteri capsule
|
58999©
|
Genital surgery procedure
|
76000©
|
Fluoroscope examination
|
76001©
|
Fluoroscope exam extensive
|
76873©
|
Echograp trans r pros study
|
76965©
|
Echo guidance radiotherapy
|
77261©
|
Radiation therapy planning (Non-OPPS only)
|
77262©
|
Radiation therapy planning (Non-OPPS only)
|
77263©
|
Radiation therapy planning (Non-OPPS only)
|
77280©
|
Set radiation therapy field
|
77285©
|
Set radiation therapy field
|
77290©
|
Set radiation therapy field
|
77295©
|
Set radiation therapy field
|
77300©
|
Radiation therapy dose plan
|
77326©
|
Brachytx isodose calc simp
|
77327©
|
Brachytx isodose calc interm
|
77328©
|
Brachytx isodose plan compl
|
77332©
|
Radiation treatment aid(s)
|
77333©
|
Radiation treatment aid(s)
|
77334©
|
Radiation treatment aid(s)
|
77336©
|
Radiation physics consult
|
77370©
|
Radiation physics consult
|
77470©
|
Special radiation treatment
|
77750©
|
Infuse radioactive materials
|
77761©
|
Apply intrcav radiat simple
|
77762©
|
Apply intrcav radiat interm
|
77763©
|
Apply intrcav radiat compl
|
77776©
|
Apply interstit radiat simpl
|
77777©
|
Apply interstit radiat inter
|
77778©
|
Apply interstit radiat compl
|
77785©
|
hdr brachytx 1 channel
|
77786©
|
hdr brachytx 2-12 channel
|
77787©
|
hdr brachytx over 12 chan
|
77789©
|
Apply surface radiation
|
77790©
|
Radiation handling
|
77799©
|
Radium/radioisotope therapy
|
Q3001©
|
Radioelements for brachytherapy, any type, each (Non-OPPS only)
|
Billing for Brachytherapy Sources – General
Brachytherapy sources (e.g., brachytherapy devices or seeds, solutions) are paid separately from the services to administer and deliver brachytherapy in the OPPS, per section 1833(t)(2)(H) of the Act, reflecting the number, isotope, and radioactive intensity of devices furnished, as well as stranded versus non-stranded configurations of sources. Therefore, providers must bill for brachytherapy sources in addition to the brachytherapy services with which the sources are applied, in order to receive payment for the sources. The separately payable sources are found in Addendum B of the most recent OPPS annual update published on the CMS web site. New sources meeting the OPPS definition of a brachytherapy source may be added for payment beginning any quarter, and the new source codes and descriptors are announced in recurring update notifications.
Each unit of a billable source is identified by the unit measurement in the respective source’s long descriptor. Seed-like sources are generally billed and paid “per source” based on the number of units of the source HCPCS code reported, including the billing of the number of sources within a stranded configuration of sources. Providers therefore must bill the number of units of a source used with the brachytherapy service rendered.
Definition of Brachytherapy Source for Separate Payment
Brachytherapy sources eligible for separate billing and payment must be radioactive sources, meaning that the source contains a radioactive isotope. Separate brachytherapy source payments reflect the number, isotope, and radioactive intensity of sources furnished to patients, as well as stranded and non-stranded configurations.
Billing of Brachytherapy Sources Ordered for a Specific Patient
A hospital may report and charge Medicare and the Medicare beneficiary for all brachytherapy sources that are ordered by the physician for a specific patient, acquired by the hospital, and used in the care of the patient. Specifically, brachytherapy sources prescribed by the physician in accordance with high quality clinical care, acquired by the hospital, and actually implanted in the patient may be reported and charged. In the case where most, but not all, prescribed sources are implanted in the patient, CMS will consider the relatively few brachytherapy sources that were ordered but not implanted due to specific clinical considerations to be used in the care of the patient and billable to Medicare under the following circumstances. The hospital may charge for all sources if they were specifically acquired by the hospital for the particular patient according to a physician’s prescription for the sources that was consistent with standard clinical practice and high quality brachytherapy treatment, in order to ensure that the clinically appropriate number of sources was available for the implantation procedure, and they were not implanted in any other patient. Those sources that were not implanted must have been disposed of in accordance with all appropriate requirements for their handling. In general, the number of sources used in the care of the patient but not implanted would not be expected to constitute more than a small fraction of the sources actually implanted in the patient. Under these circumstances, the beneficiary is liable for the copayment for all the sources billed to Medicare.
Billing for Brachytherapy Source Supervision, Handling and Loading Costs
Providers should report charges related to supervision, handling, and loading of radiation sources, including brachytherapy sources, in one of two ways:
1. Report the charge separately using CPT code 77790 (Supervision, handling, loading of radiation source), in addition to reporting the associated HCPCS procedure code(s) for application of the radiation source;
2. Include the supervision, handling, and/or loading charges as part of the charge reported with the HCPCS procedure code(s) for application of the radiation source.
Do not bill a separate charge for brachytherapy source storage costs. These costs are treated as part of the department’s overhead costs.
Payment for New Brachytherapy Sources
Not otherwise specified (NOS) brachytherapy source codes are available for payment of new brachytherapy sources for which source codes have not yet been established: C2698 (Brachytherapy source, stranded, not otherwise specified, per source), and C2699 (Brachytherapy source, non-stranded, not otherwise specified, per source). The payment rates for these NOS codes are based on a rate equal to the lowest stranded or non-stranded payment rate for such sources, respectively, on a per source basis (as opposed, for example, to per mCi). Once CMS establishes a new HCPCS code for a new source, the new code will be assigned to its own APC, with the payment rate set based on consideration of external data and other relevant information, until claims data are available for the standard OPPS rate making methodology.
Correspondence Language Policy/Example Number 6.70000 – CPT “separate procedure” definition
For example, the code descriptor for CPT code 76000 (“Fluoroscopy (separate procedure), up to one hour physician time, other than 71023 or 71034 (eg, cardiac fluoroscopy)”) includes the “separate procedure” designation. When radiological supervision and interpretation (RS&I) for percutaneous transhepatic biliary drainage with contrast monitoring (CPT code 75980) is performed, the procedure described by CPT code 76000 does not meet the definition of a “separate procedure”. Therefore, CPT code 76000 cannot be reported separately and is bundled into CPT code 75980. Correspondence Language Policy/Example Number 7.70000 – More extensive procedure
For example, CPT code 72240 describes radiologic supervision and interpretation (RS&I) for cervical myelography. CPT code 72270 describes RS&I for myelography of two or more spinal regions (i.e. cervical/thoracic region, lumbar/thoracic region, lumbar/cervical region). If the myelography RS&I performed includes two or more spinal regions, one of which is the cervical region, the procedure described by CPT code 72270 is more extensive than the one described by CPT code 72240. Therefore, CPT code 72240 is bundled into CPT code 72270.
Extremity Imaging
Global and Physician Professional Payment coding & reimbursement guide 2017 SKELETAL HEALTH SOLUTIONS Additional Information:
1. Fluoroscopy reported as CPT Codes 76000 or 76001 is integral to many procedures including, but not limited, to most spinal, endoscopic, and injection procedures and should not be reported separately. For some of these procedures, there are separate fluoroscopic guidance codes which may be reported separately.
2. Fluoroscopic guidance reported as CPT 77002 is considered “bundled” with certain arthrography supervision and interpretation services (i.e., CPT Codes 73085, 73115, 73580 and 73615).
NCCI Procedure-to-Procedure (PTP) edits can be found on the CMS website: https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/index.htm
1. American Medical Association (AMA), 2017 Current Procedural Terminology (CPT), Professional Edition. CPT codes and descriptions only are copyright 2016 AMA. All rights reserved. The AMA assumes no liability for data contained herein. No fee schedules, basic units, relative or related listings are included in CPT. Applicable FARS/DFARS Restrictions Apply for Government Use. Centers for Medicare & Medicaid Services (CMS), 2017 Healthcare Common Procedure Coding System (HCPCS) codes, available at http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.
2. The 2017 physician relative value units (RVUs) are from the 2016 RVU file available on the CMS website at
3. The national average 2016 Medicare rates to physicians shown are based on the 2017 conversion factor of $35.8887 and do not reflect payment cuts due to sequestration. Medicare payment for a given procedure in a given locality in 2017 should be available in the Medicare Physician Fee Schedule Look-up file accessible through the CMS website at
http://www.cms.gov/apps/physician-fee-schedule/overview. aspx. Any payment rates listed may be subject to change without notice. Actual payment to a physician will vary based on geographic location and may also differ based on policies and fee schedules outlined as terms in your health plan and/or payer contracts.
Hologic Inc., provides this coding guide for informational purposes only. This guide is not an affirmative instruction as to which codes and modifiers to use for a particular service, supply, procedure or treatment. It is the provider’s responsibility to determine and submit the appropriate codes and modifiers for any service, supply, procedure or treatment rendered.
Actual codes and/or modifiers
used are at the sole discretion of the treating physician and/or facility. Contact your local payer for specific coding and coverage guidelines. Hologic cannot guarantee medical benefit coverage or reimbursement with the codes listed in this guide.
ICD-9-CM Codes That Support Medical Necessity
140.0–140.1
|
Malignant neoplasm of lip
|
140.3–140.6
|
Malignant neoplasm of lip
|
140.8–140.9
|
Malignant neoplasm of lip
|
141.0–141.6
|
Malignant neoplasm of tongue
|
141.8–141.9
|
Malignant neoplasm of tongue
|
142.0–142.2
|
Malignant neoplasm of major salivary glands
|
142.8–142.9
|
Malignant neoplasm of major salivary glands
|
143.0–143.1
|
Malignant neoplasm of gum
|
143.8–143.9
|
Malignant neoplasm of gum
|
144.0–144.1
|
Malignant neoplasm of floor of mouth
|
144.8–144.9
|
Malignant neoplasm of floor of mouth
|
145.0–145.6
|
Malignant neoplasm of other and unspecified parts of mouth
|
145.8–145.9
|
Malignant neoplasm of other and unspecified parts of mouth
|
146.0–146.9
|
Malignant neoplasm of oropharynx
|
147.0–147.3
|
Malignant neoplasm of nasopharynx
|
147.8–147.9
|
Malignant neoplasm of nasopharynx
|
148.0–148.3
|
Malignant neoplasm of hypopharynx
|
148.8–148.9
|
Malignant neoplasm of hypopharynx
|
149.0–149.1
|
Malignant neoplasm of other and ill-defined sites within lip, oral cavity and pharynx
|
149.8–149.9
|
Malignant neoplasm of other and ill-defined sites within lip, oral cavity and pharynx
|
150.0–150.5
|
Malignant neoplasm of esophagus
|
150.8–150.9
|
Malignant neoplasm of esophagus
|
151.0–151.6
|
Malignant neoplasm of stomach
|
151.8–151.9
|
Malignant neoplasm of stomach
|
152.0–152.3
|
Malignant neoplasm of small intestine, including duodenum
|
152.8–152.9
|
Malignant neoplasm of small intestine, including duodenum
|
153.0–153.9
|
Malignant neoplasm of hepatic flexure
|
154.0–154.3
|
Malignant neoplasm of rectum, rectosigmoid junction and anus
|
154.8
|
Malignant neoplasm of other sites of rectum rectosigmoid junction and anus
|
155.0–155.2
|
Malignant neoplasm of liver and intrahepatic bile ducts
|
156.0–156.2
|
Malignant neoplasm of gallbladder and extrahepatic bile ducts
|
156.8–156.9
|
Malignant neoplasm of gallbladder and extrahepatic bile ducts
|
157.0–157.4
|
Malignant neoplasm of pancreas
|
157.8–157.9
|
Malignant neoplasm of pancreas
|
158.0
|
Malignant neoplasm of retroperitoneum
|
158.8–158.9
|
Malignant neoplasm of retroperitoneum and peritoneum
|
159.0–159.1
|
Malignant neoplasm of other and ill-defined sites within digestive organs and peritoneum
|
159.8–159.9
|
Malignant neoplasm of other and ill-defined sites within digestive organs and peritoneum
|
160.0–160.5
|
Malignant neoplasm of nasal cavities, middle ear and accessory sinuses
|
160.8–160.9
|
Malignant neoplasm of nasal cavities, middle ear and accessory sinuses
|
161.0–161.3
|
Malignant neoplasm of larynx
|
161.8–161.9
|
Malignant neoplasm of larynx
|
162.0
|
Malignant neoplasm of trachea
|
162.2–162.5
|
Malignant neoplasm of trachea, bronchus and lung
|
162.8–162.9
|
Malignant neoplasm of trachea, bronchus and lung
|
163.0–163.1
|
Malignant neoplasm of pleura
|
163.8–163.9
|
Malignant neoplasm of pleura
|
164.0–164.3
|
Malignant neoplasm of thymus, heart and mediastinum
|
164.8–164.9
|
Malignant neoplasm of thymus, heart and mediastinum
|
165.0
|
Malignant neoplasm of upper respiratory tract part unspecified
|
165.8–165.9
|
Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs
|
170.0–170.9
|
Malignant neoplasm of bone and articular cartilage
|
171.0
|
Malignant neoplasm of connective and other soft tissue of head face and neck
|
171.2–171.9
|
Malignant neoplasm of connective and other soft tissue
|
172.0–172.9
|
Malignant melanoma of skin
|
173.0–173.9
|
Other malignant neoplasm of skin
|
174.0–174.6
|
Malignant neoplasm of female breast
|
174.8–174.9
|
Malignant neoplasm of female breast
|
175.0
|
Malignant neoplasm of nipple and areola of male breast
|
175.9
|
Malignant neoplasm of other and unspecified sites of male breast
|
176.0–176.5
|
Kaposi’s sarcoma
|
176.8–176.9
|
Kaposi’s sarcoma
|
179
|
Malignant neoplasm of uterus-part uns
|
180.0–180.1
|
Malignant neoplasm of cervix uteri
|
180.8–180.9
|
Malignant neoplasm of cervix uteri
|
181
|
Malignant neoplasm of placenta
|
182.0–182.1
|
Malignant neoplasm of body of uterus
|
182.8
|
Malignant neoplasm of other specified sites of body of uterus
|
183.0–183.5
|
Malignant neoplasm of ovary and other uterine adnexa
|
183.8–183.9
|
Malignant neoplasm of ovary and other uterine adnexa
|
184.0–184.4
|
Malignant neoplasm of other and unspecified female genital organs
|
184.8–184.9
|
Malignant neoplasm of other and unspecified female genital organs
|
185
|
Malignant neoplasm of prostate
|
186.0
|
Malignant neoplasm of undescended testis
|
186.9
|
Malignant neoplasm of other and unspecified testis
|
187.1–187.9
|
Malignant neoplasm of penis and other male genital organs
|
188.0–188.9
|
Malignant neoplasm of bladder
|
189.0–189.4
|
Malignant neoplasm of kidney and other and unspecified urinary organs
|
189.8–189.9
|
Malignant neoplasm of kidney and other and unspecified urinary organs
|
190.0–190.9
|
Malignant neoplasm of eye
|
191.0–191.9
|
Malignant neoplasm of brain
|
192.0–192.3
|
Malignant neoplasm of other and unspecified parts of nervous system
|
192.8–192.9
|
Malignant neoplasm of other and unspecified parts of nervous system
|
193
|
Malignant neoplasm of thyroid gland
|
194.0–194.1
|
Malignant neoplasm of other endocrine glands and related structures
|
194.3–194.6
|
Malignant neoplasm of other endocrine glands and related structures
|
194.8–194.9
|
Malignant neoplasm of other endocrine glands and related structures
|
195.0–195.5
|
Malignant neoplasm of other and ill-defined sites
|
195.8
|
Malignant neoplasm of other specified sites
|
196.0–196.3
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
196.5–196.6
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
196.8–196.9
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
197.0–197.8
|
Secondary malignant neoplasm of respiratory and digestive systems
|
198.0–198.7
|
Secondary malignant neoplasm of other specified sites
|
198.81–198.82
|
Other specified sites
|
198.89
|
Other specified sites
|
199.0–199.2
|
Malignant neoplasm within specification of site
|
200.00–200.08
|
Reticulosarcoma
|
200.10–200.18
|
Lymphosarcoma
|
200.20–200.28
|
Burkitt’s tumor or lymphoma
|
200.30–200.38
|
Marginal zone lymphoma
|
200.40–200.48
|
Mantle cell lymphoma
|
200.50–200.58
|
Primary central nervous system lymphoma
|
200.60–200.68
|
Anaplastic large cell lymphoma
|
200.70–200.78
|
Large cell lymphoma
|
200.80–200.88
|
Other named variants
|
201.00–201.08
|
Hodgkin’s paragranuloma
|
201.10–201.18
|
Hodgkin’s granuloma
|
201.20–201.28
|
Hodgkin’s sarcoma
|
201.40–201.48
|
Lymphocytic-histiocytic predominance
|
201.50–201.58
|
Nodular sclerosis
|
201.60–201.68
|
Mixed cellularity
|
201.70–201.78
|
Lymphocytic depletion
|
201.90–201.98
|
Hodgkin’s disease unspecified
|
202.00–202.08
|
Nodular lymphoma
|
202.10–202.18
|
Mycosis fungoides
|
202.20–202.28
|
Sezary’s disease
|
202.30–202.38
|
Malignant histiocytosis
|
202.40–202.48
|
Leukemic reticuloendotheliosis
|
202.50–202.58
|
Letterer-siwe disease
|
202.60–202.68
|
Malignant mast cell tumors
|
202.80–202.88
|
Other lymphomas
|
202.90–202.98
|
Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue
|
203.00–203.02
|
Multiple myeloma
|
203.10–203.12
|
Plasma cell leukemia
|
203.80–203.82
|
Other immunoproliferative neoplasms
|
204.00–204.02
|
Acute (Lymphoid leukemia)
|
204.10–204.12
|
Chronic (Lymphoid leukemia)
|
204.20–204.22
|
Subacute (Lymphoid leukemia)
|
204.80–204.82
|
Other lymphoid leukemia
|
204.90–204.92
|
Unspecified lymphoid leukemia
|
205.00–205.02
|
Acute (Myeloid leukemia)
|
205.10–205.12
|
Chronic (Myeloid leukemia)
|
205.20–205.22
|
Subacute
|
205.30–205.32
|
Myeloid sarcoma
|
205.80–205.82
|
Other myeloid leukemia
|
205.90–205.92
|
Unspecified myeloid leukemia
|
206.00–206.02
|
Acute (Monocytic leukemia)
|
206.10–206.12
|
Chronic (Monocytic leukemia)
|
206.20–206.22
|
Subacute (Monocytic leukemia)
|
206.80–206.82
|
Other monocytic leukemia
|
206.90–206.92
|
Unspecified monocytic leukemia
|
207.00–207.02
|
Acute erythremia and erythroleukemia
|
207.10–207.12
|
Chronic erythremia
|
207.20–207.22
|
Megakaryocytic leukemia
|
207.80–207.82
|
Other specified leukemia
|
208.00–208.02
|
Acute (Leukemia of unspecified cell type)
|
208.10–208.12
|
Chronic (Leukemia of unspecified cell type)
|
208.20
|
Subacute (Leukemia of unspecified cell type)
|
208.80–208.82
|
Other leukemia of unspecified cell type
|
208.90–208.92
|
Unspecified leukemia
|
233.0
|
Carcinoma in situ of breast
|
235.0–235.9
|
Neoplasm of uncertain behavior of digestive and respiratory systems
|
236.0–236.7
|
Neoplasm of uncertain behavior of genitourinary organs
|
236.90–236.99
|
Other and unspecified urinary organs
|
237.0–237.6
|
Neoplasm of uncertain behavior of endocrine glands and nervous system
|
237.70–237.73
|
Neurofibromatosis
|
237.79
|
Other neurofibromatosis
|
237.9
|
Other and unspecified parts of nervous system
|
238.0–238.6
|
Neoplasm of uncertain behavior of other and unspecified sites and tissues
|
238.71–238.77
|
Neoplasm of other lymphatic and hematopoietic tissues
|
238.79
|
Neoplasm of other lymphatic and hematopoietic tissues
|
238.8–238.9
|
Neoplasm of uncertain behavior of other and unspecified sites and tissues
|
372.40–372.45
|
Pterygium
|
- Documentation supporting medical necessity should be legible, maintained in the patient’s medical record and made available to Medicare upon request.
- Documentation supporting the medical necessity of these services, such as ICD-9-CM codes, must be submitted with each claim. Claims submitted without such evidence will be denied as not medically necessary.
- The treatment goal must be documented (curative, palliative or tumor control) in the medical record.
- The record must contain documentation of the patient’s informed consent to treatment.
- A written, signed and dated prescription or treatment plan designed by the radiation oncologist must be on file. The prescription must include all the following information: designation of the treatment site, the isotope and the number of source positions, and the planned dose to each point.
- Given the multiplicity of services that are inherent in brachytherapy, it is essential that the medical records reflect each service in a clear, linear and temporally logical form. Flow charts, where helpful, are recommended. All procedures must be documented with a procedural note.